Evidence map›Paper›PMID 42233993›Full record

ArticleActa neurochirurgica2026

Assessing radiological response of IDH-mutated glioma to vorasidenib by tumor diameter slopes: a series of 8 cases.

Emmanuel Mandonnet

Abstract read
In one paragraph

Article in Acta neurochirurgica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Emmanuel MandonnetDepartment of Neurosurgery, Lariboisière Hospital, AP-HP, 2 Rue Ambroise Paré, 75010, Paris, France. emmanuel.mandonnet@aphp.fr.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The INDIGO trial demonstrated improved progression-free survival under vorasidenib in IDH-mutated grade 2 glioma patients. However, the pattern of vorasidenib effects remains unknown. We thus performed a retrospective analysis of tumor kinetics in eight patients enrolled in the INDIGO trial. Tumor diameters (computed from FLAIR volumetry) and their slopes were individually estimated, before and under vorasidenib. Three patients showed no change in slope. Three patients exhibited a marked slope decrease, and two demonstrated slope inversion. Tumor diameter slopes allows individual assessment of radiological response, providing clinically relevant insights that cannot be captured by the cohort-level analysis performed in the INDIGO trial.

Indexed as

Antineoplastic AgentsBrain NeoplasmsGliomaIsocitrate DehydrogenaseTriazinesAdultAgedFemaleHumansMagnetic Resonance ImagingMaleMiddle AgedMutationRetrospective StudiesAntineoplastic AgentsIDH1 protein, humanIsocitrate DehydrogenaseTriazinesdiameter slopesgrowth rateIDH-mutated gliomavorasidenib

Identifiers

PMID42233993
PMCPMC13427936

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.